Enclomiphene vs Testosterone Cypionate

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners

Mechanism

Testosterone cypionate is an esterified prodrug of testosterone that undergoes hydrolysis in vivo to release free testosterone. It binds the androgen receptor (AR), activating genomic pathways via AR nuclear translocation and transcription of anabolic genes including IGF-1, satellite cell proliferation, and nitrogen retention. Additionally, testosterone exerts non-genomic effects through membrane-associated AR signaling, modulating calcium influx and MAPK/ERK pathways. Aromatization to estradiol via CYP19A1 (aromatase) maintains bone density and lipid profiles.

Standard Dosing

Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy.

Timing

Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm.

Cycle Duration

Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation.

Side Effects

• Polycythemia / elevated hematocrit
• Acne and oily skin
• Testicular atrophy (without hCG)
• Gynecomastia (from aromatization)
• Mood changes and irritability
• Fluid retention
• Elevated liver enzymes (rare with injectable)
• Sleep apnea exacerbation

Contraindications

• Prostate cancer or elevated PSA without urological clearance
• Male breast cancer
• Polycythemia (hematocrit >54%)
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Desire for near-term fertility (without hCG adjunct)
• Women who are pregnant or may become pregnant

Best Stacking Partners